EHS
EHS

Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review


    • Mujtaba B.
    • Wang F.
    • Taher A.
    • et al.

    Dermatofibrosarcoma protuberans: pathological and imaging review.

    Curr Probl Diagn Radiol. 2021; 50: 236-240

    • Acosta A.E.
    • Velez C.S.

    Dermatofibrosarcoma protuberans.

    Curr Treat Options Oncol. 2017; 18: 56

    • Allen A.
    • Ahn C.
    • Sangueza O.P.

    Dermatofibrosarcoma protuberans.

    Dermatol Clin. 2019; 37: 483-488

    • Malan M.
    • Xuejingzi W.
    • Quan S.J.

    The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.

    Pan Afr Med J. 2019; 33: 297

    • Mendenhall W.M.
    • Zlotecki R.A.
    • Scarborough M.T.

    Dermatofibrosarcoma protuberans. Cancer. 2004; 101: 2503-2508

    • Noujaim J.
    • Thway K.
    • Fisher C.
    • Jones R.L.

    Dermatofibrosarcoma protuberans: from translocation to targeted therapy.

    Cancer Biol Med. 2015; 12: 375-384

    • Sirvent N.
    • Maire G.
    • Pedeutour F.

    Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.

    Genes Chromosomes Cancer. 2003; 37: 1-19

    • Simon M.P.
    • Pedeutour F.
    • Sirvent N.
    • et al.

    Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.

    Nat Genet. 1997; 15: 95-98

    • Stacchiotti S.
    • Pantaleo M.A.
    • Negri T.
    • et al.

    Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP).

    Clin Cancer Res. 2016; 22: 837-846

    • Koster J.
    • Arbajian E.
    • Viklund B.
    • et al.

    Genomic and transcriptomic features of dermatofibrosarcoma protuberans: unusual chromosomal origin of the COL1A1-PDGFB fusion gene and synergistic effects of amplified regions in tumor development.

    Cancer Genet. 2020; 241: 34-41

    • Liang C.A.
    • Jambusaria-Pahlajani A.
    • Karia P.S.
    • Elenitsas R.
    • Zhang P.D.
    • Schmults C.D.

    A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change.

    J Am Acad Dermatol. 2014; 71: 781-786

    • Ugurel S.
    • Kortmann R.D.
    • Mohr P.
    • et al.

    S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018.

    J Dtsch Dermatol Ges. 2019; 17: 663-668

  • Dermatofibrosarcoma Protuberans (Version 1.2018). National Comprehensive Cancer Network,
    2018 (Published)

    • Rutkowski P.
    • Debiec-Rychter M.

    Current treatment options for dermatofibrosarcoma protuberans.

    Expert Rev Anticancer Ther. 2015; 15: 901-909

    • Ballo M.T.
    • Zagars G.K.
    • Pisters P.
    • Pollack A.

    The role of radiation therapy in the management of dermatofibrosarcoma protuberans.

    Int J Radiat Oncol Biol Phys. 1998; 40: 823-827

    • Suit H.
    • Spiro I.
    • Mankin H.J.
    • Efird J.
    • Rosenberg A.E.

    Radiation in management of patients with dermatofibrosarcoma protuberans.

    J Clin Oncol. 1996; 14: 2365-2369

    • Chen Y.T.
    • Tu W.T.
    • Lee W.R.
    • Huang Y.C.

    The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis.

    J Eur Acad Dermatol Venereol. 2016; 30: 1107-1114

    • Santos W.M.D.
    • Secoli S.R.
    • Püschel VAdA.

    The Joanna Briggs Institute approach for systematic reviews.

    Rev Lat Am Enfermagem. 2018; 26 (e3074-e3074)

    • Page M.J.
    • McKenzie J.E.
    • Bossuyt P.M.
    • et al.

    The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

    BMJ. 2021; 372: n71

    • Ouzzani M.
    • Hammady H.
    • Fedorowicz Z.
    • Elmagarmid A.

    Rayyan-a web and mobile app for systematic reviews.

    Syst Rev. 2016; 5: 210

  • Moola S MZ, Tufanaru C, Aromataris E, et al. Chapter 7: systematic reviews of etiology and risk. In: Aromataris E MZ, ed. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute2017: https://reviewersmanual.joannabriggs.org/.

    • Dagan R.
    • Morris C.G.
    • Zlotecki R.A.
    • Scarborough M.T.
    • Mendenhall W.M.

    Radiotherapy in the treatment of dermatofibrosarcoma protuberans.

    Am J Clin Oncol. 2005; 28: 537-539

    • Bandyopadhyay A.
    • Biswas S.
    • Sepai H.M.
    • Basu P.
    • Ghosh A.K.

    Outcome of surgery and radiotherapy for dermatofibrosarcoma protuberans: 5-year experience from two tertiary centers of eastern India.

    Journal of Radiation Oncology. 2019; 8: 405-412

    • Kashyap L.N.V.
    • Patil V.
    • Joshi A.
    • Mahajan A.
    • Mittal N.
    • Prabhash K.

    Dermatofibrosarcoma protuberans of head and neck: clinical outcome of nine cases treated with imatinib.

    Cancer Res Stat Treat. 2019; 2: 112-118

    • McArthur G.A.
    • Demetri G.D.
    • van Oosterom A.
    • et al.

    Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib Target Exploration Consortium Study B2225.

    J Clin Oncol. 2005; 23: 866-873

    • Rastogi S.
    • Dhamija E.
    • Barwad A.
    • Aggarwal A.
    • Sharma A.
    • Panday R.

    Advanced dermatofibrosarcoma protuberans treatment with imatinib: experience from a dedicated sarcoma medical oncology clinic in India.

    J Glob Oncol. 2018; 4: 1-7

    • Rutkowski P.
    • Klimczak A.
    • Lugowska I.
    • et al.

    Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate – the impact of fibrosarcomatous transformation.

    Eur J Surg Oncol. 2017; 43: 1134-1141

    • Fu Y.
    • Kang H.
    • Zhao H.
    • et al.

    Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.

    Int J Clin Exp Med. 2015; 8: 8288-8294

    • Rutkowski P.
    • Debiec-Rychter M.
    • Nowecki Z.
    • et al.

    Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.

    J Eur Acad Dermatol Venereol. 2011; 25: 264-270

    • Wang C.
    • Luo Z.
    • Chen J.
    • et al.

    Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.

    Medicine (Baltim). 2015; 94: e773

    • Delyon J.
    • Porcher R.
    • Battistella M.
    • et al.

    A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans.

    J Invest Dermatol. 2021; 141 (e762): 761-769

    • Rutkowski P.
    • Van Glabbeke M.
    • Rankin C.J.
    • et al.

    Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

    J Clin Oncol. 2010; 28: 1772-1779

    • Heinrich M.C.
    • Joensuu H.
    • Demetri G.D.
    • et al.

    Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

    Clin Cancer Res. 2008; 14: 2717-2725

    • McArthur G.A.

    Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.

    J Natl Compr Cancer Netw. 2007; 5: 557-562

    • Lemm D.
    • Mugge L.O.
    • Mentzel T.
    • Hoffken K.

    Current treatment options in dermatofibrosarcoma protuberans.

    J Cancer Res Clin Oncol. 2009; 135: 653-665

    • Navarrete-Dechent C.
    • Mori S.
    • Barker C.A.
    • Dickson M.A.
    • Nehal K.S.

    Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review.

    JAMA Dermatol. 2019; 155: 361-369



  • Source link

    EHS
    Back to top button